News

In a recent letter to the editor, a newly-developed tool to assess one’s satisfaction with life when dealing with food allergy was introduced.

The gene expression analysis of the liver showed mRNA levels of BCAT1, BCAT2, and BCKDA were upregulated in patients with NAFLD.

A recent study reviewed several educational interventions designed to promote food allergy literacy and knowledge for both parents and children.

The results show 28.9% of the aripiprazole augmentation group achieved remission, compared to 28.2% of the bupropion augmentation group and 19.3% of the bupropion switch group.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

At the AAAAI 2023 Annual Meeting, Dr. Debajyoti Ghosh explains the importance of understanding the effect of phthalates, specifically di-2-ethylhexyl phthalate (DEHP).

In an interview at ACC 2023, Ankeet Bhatt, MD, describes how virtual care team represents an effective and scalable approach to improve therapeutic optimization across a health system.

Mary McGowan, MD, discusses a study she presented examining the overall prevalence of patients with high-risk hypercholesterolemia who fail to meet guideline-recommended goals for LDL-C levels.

In an interview at ACC 2023, Harrington elaborated on the upcoming phase 3 Librexia clinical trial program studying the Factor XIa inhibitor for the prevention of thrombotic events.

New data from a study on adult vitiligo patients indicates that both autoimmune/autoinflammatory and non-autoimmune comorbidities have higher occurrence rates for vitiligo patients.

The mortality rate ranged from 13.2 deaths per 100,000 live births in 2005 to 8.3 deaths per 100,000 live births in 2020.

The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.

New findings have indicated that alopecia areata, alopecia totalis, and alopecia universalis, may disproportionately affect Asian Americans and other people of color.

Much of the recent focus on drug development in IBD has centered on the IL-23 pathway.

At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.

An interview with Dr. Annapoorna S. Kini at ACC 2023 breaks down the findings on the effect of evolocumab on coronary plaque characteristics in stable CAD from the YELLOW III study.

Steve Nissen, MD, sits down for an interview to discuss the clinical takeaways, design intricacies, safety signals, and more from the CLEAR Outcomes trial.

Implantation of a pacemaker to enhance exercise heart rate did not improve exercise capacity, symptoms, or exercise cardiac output in patients with HFpEF and chronotropic incompetence in the RAPID-HF trial.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

In the largest implementation trial ever conducted, new research from the NUDGE FLU trial suggests informing patients of the potential cardiovascular benefits associated with receipt of the flu vaccine could increase uptake among older adults.

In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.

Clyde Yancy, MD, offers insight into his keynote address and the importance of both recognizing and addressing inequities within heart failure management.

In a Q&A at ACC 2023, Drs. Alexandra Murphy and Birgit Vogel of Mount Sinai discuss sex-specific predictors of MACE and the need for individualization of care to achieve equity in cardiovascular health.

At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.

Results from the STOP-CA trial suggest patients taking atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo.

The TRILUMINATE Pivotal trial reports a reduction in the severity of tricuspid regurgitation with TEER, but no significant difference in survival or hospitalization after one year of follow-up.